Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Other material
confidence 65%
filed 2026-05-27
Item 5.03
The filing discloses an amendment to the Certificate of Designation increasing authorized Series B Cumulative Convertible Preferred Stock from 397,222 to 572,222 shares (a 44% increase). While this is a structural/governance change disclosed under Item 5.03, the material substance is an expansion of convertible preferred equity capacity, which could signal dilution risk or capital-raising activity. This does not fit neatly into the more specific categories (it is not a dilutive issuance itself, nor a routine bylaw amendment), so other_material is most appropriate.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-27
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of TransAct Technologies' 2026 Annual Meeting of Stockholders held on May 26, 2026. The filing presents voting results for three proposals: election of six directors (Dillon, Dunning, Friedberg, Friedman, Hilario, and Olinger), ratification of CBIZ CPAs P.C. as independent auditor, and an advisory vote on executive compensation. All proposals passed with substantial majorities. Shareholder vote results are material to investors as they reflect governance outcomes and stockholder preferences.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-27
Item 5.03
The filing discloses stockholder approval of an Amended and Restated Certificate of Incorporation that effects board declassification and eliminates supermajority voting requirements, along with corresponding bylaw amendments. While Item 5.03 covers amendments to articles and bylaws, these governance changes are material to investors as they fundamentally alter board composition mechanics and voting thresholds, affecting shareholder rights and corporate control dynamics. This does not fit neatly into the more specific event categories (e.g., it is not an executive appointment, departure, or compensation matter), warranting classification as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-27
Item 2.03
This disclosure reports the creation of direct financial obligations through the issuance of consolidated obligations (bonds and discount notes) by the Federal Home Loan Bank of Des Moines. While Item 2.03 typically captures covenant breaches or material debt arrangements, this filing describes routine debt issuance activity that is material to the Bank's operations but does not fit cleanly into the covenant_breach category (no breach or default is disclosed). The Bank explicitly states "consolidated obligations issuance is material to the Bank," and Schedule A details committed issuances, making this a material event that warrants disclosure but falls outside the more specific event-type categories.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-27
Item 2.03
This 8-K Item 2.03 discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds and discount notes totaling approximately $560 million across five separate issuances with varying maturities (2026–2034) and coupon rates (3.83%–5.08%). While Item 2.03 typically signals covenant_breach or debt acceleration events, this filing describes routine debt issuance by a Federal Home Loan Bank in the ordinary course of business—a material financing activity that does not fit the specific covenant_breach taxonomy (which implies a triggering default or acceleration). The disclosure is material to investors assessing the registrant's capital structure and funding activities, but the event itself is a standard debt offering rather than a breach or distress signal.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-27
Item 2.03
This Item 2.03 disclosure reports the issuance of consolidated obligation bonds totaling approximately $390 million across three debt securities (trade dates 5/20–5/22/2026, maturing 2027–12/2027). While the filing explicitly states "consolidated obligations issuance is material to the Bank," the event does not fit cleanly into the standard taxonomy: it is neither a covenant breach (no default triggered), nor a dilutive equity issuance, nor a restatement or going-concern disclosure. The creation of direct financial obligations through routine debt issuance by a Federal Home Loan Bank is material to investors but represents ordinary course funding activity rather than an extraordinary event, warranting classification as other_material.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-05-27
Item 2.02
The filing discloses Phreesia's financial results for the fiscal first quarter ended April 30, 2026 through a press release and stakeholder letter furnished as exhibits. This is a standard quarterly earnings announcement under Item 2.02, which is material to investors as it provides periodic financial performance data.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-27
Item 5.07
This is a clear disclosure of shareholder vote results from PCB Bancorp's annual meeting held on May 27, 2026. The filing reports voting outcomes on three proposals: election of eight directors, an advisory vote on executive compensation (approved with 8,493,476 votes for), and ratification of Crowe LLP as independent auditor (approved with 10,015,747 votes for). This is a quintessential Item 5.07 disclosure and is material as it reflects shareholder approval of key governance matters.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-05-27
Item 2.02
The filing discloses financial results for the fourth quarter and full fiscal year ended March 31, 2026, with the press release attached as Exhibit 99.1. This is a standard earnings release announcement under Item 2.02, which is material to investors as it provides periodic financial performance information.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-27
The filing discloses results of Business First Bancshares' annual shareholder meeting held on May 21, 2026, under Item 5.07. The company reports voting outcomes on three proposals: election of 16 directors, non-binding advisory approval of named executive officer compensation, and ratification of Forvis Mazars, LLP as independent auditor. The detailed voting tallies for each director and proposal are provided, with 72.62% shareholder attendance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-27
Item 5.07
This is a clear disclosure of shareholder voting results from the 2026 Annual Meeting of Stockholders held on May 27, 2026, filed under Item 5.07. The filing presents detailed vote tallies for three proposals: election of two Class III Directors (John Deane and W. Matt Ralls), ratification of Grant Thornton LLP as independent auditor, and advisory approval of named executive officer compensation. The disclosure includes vote counts (For, Against, Withheld, Abstentions, and Broker Non-Votes) for each proposal, which is the standard format for shareholder vote result disclosures required by Item 5.07.
View raw filing on EDGAR →
8-K
Earnings release
confidence 85%
filed 2026-05-27
Item 8.01
The filing discloses positive topline results from a Phase 3 clinical trial (ENHANCE trial) for BRIUMVI®, a marketed therapeutic. While technically a clinical trial result rather than financial earnings, this represents material clinical/commercial news about a key product that would affect investor assessment of the company's pipeline and commercial prospects. The press release announcement of trial results is the core disclosure, making this functionally equivalent to an earnings-type announcement in the biotech context.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-05-27
Item 5.02
The filing discloses the appointment of Michael Pruitt to the Board of Directors on May 20, 2026. Although the Item 5.02(d) heading references both departures and appointments, the prose centers exclusively on Pruitt's election as a director, with detailed background on his extensive public company leadership experience and expertise in emerging technology. This is a clear director appointment event.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-05-27
Item 1.01
National Healthcare Corp entered into a material acquisition of assets and real property from National Health Investors, Inc. pursuant to a Purchase and Sale Agreement dated April 21, 2026, with integrated financing through a $475 million term loan and $50 million revolving credit facility expected to close simultaneously in Q3 2026.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-27
Item 5.07
This is a clear disclosure of shareholder vote results from the 2026 annual meeting held on May 27, 2026, covering three proposals: election of seven directors, advisory vote on named executive officer compensation, and ratification of the independent auditor (Accuity LLP). The filing presents voting tallies for each proposal, which is the core content of Item 5.07 disclosures and constitutes material information about corporate governance outcomes.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-27
Item 5.07
Arbutus Biopharma held its Annual Meeting of Shareholders on May 26, 2026, with voting results on four proposals: director elections, approval of the 2026 Omnibus Share and Incentive Plan, an advisory vote on named executive officer compensation, and appointment of Ernst & Young LLP as independent auditor.
View raw filing on EDGAR →
8-K
Covenant Breach
confidence 95%
filed 2026-05-27
Item 2.04
The filing discloses demand letters from Whitehawk Capital Partners asserting two events of default under an $80 million Credit Agreement dated July 29, 2025, including alleged breaches of Sections 9.8 and 9.18 and an insolvency proceeding triggering Section 11.1(l). Whitehawk claims all obligations became automatically due and payable, with interest accruing at default rates since August 19, 2025, and has filed litigation to enjoin transfer of collateral. This is a classic covenant breach and acceleration event under Item 2.04.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-05-27
Item 2.02
Everpure issued a press release on May 27, 2026 disclosing financial results for the quarter ended May 3, 2026, with the press release furnished as Exhibit 99.1. This is a standard quarterly earnings release disclosure under Item 2.02, which is material to investors assessing the company's operational performance and financial condition.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-27
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Expensify's 2026 Annual Meeting of Stockholders held on May 22, 2026. The filing presents voting results for four proposals: election of eight directors, ratification of KPMG LLP as independent auditor, advisory approval of named executive officer compensation, and approval of reverse stock split and authorized share reduction. All proposals passed with substantial majorities, making this a routine but material shareholder vote results disclosure.
View raw filing on EDGAR →
8-K
Restatement
confidence 95%
filed 2026-05-27
Item 4.02
The Company disclosed non-reliance on previously issued financial statements in Item 4.02(a), citing failures to follow US GAAP in the timing of legal fee recognition and revenue recognition errors across three quarterly periods (March 31, June 30, and September 30, 2025 Form 10-Qs). The auditor Michael Gillespie & Associates identified that $9,840 in legal expenses should have been recorded when services were performed rather than when invoiced, and there were additional revenue recognition and prepaid fee classification errors. The Company anticipates restating these financial statements by June 30, 2026, which constitutes a material accounting restatement.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-05-27
Item 3.01
SOBR Safe received a Nasdaq deficiency letter on March 19, 2026 for failing to maintain the $1.00 minimum bid price requirement for 30 consecutive business days. Although the company obtained a stay and a conditional extension until September 15, 2026 to regain compliance (contingent on completing a business combination with Clean World Ventures and demonstrating compliance with Initial Listing Rules), the filing explicitly discloses the delisting risk and the conditions precedent to continued listing, which is the core substance of Item 3.01.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-27
The filing discloses entry into an At-The-Market (ATM) Issuance Sales Agreement on May 26, 2026, permitting the Company to offer and sell up to $5,000,000 of common stock through Alexander Capital. This is a classic dilutive equity issuance under Item 1.01. The forward-looking statements also reference the Company's need to regain compliance with Nasdaq's Stockholders' Equity Requirement, signaling financial stress and the use of equity issuance as a capital-raising mechanism.
View raw filing on EDGAR →
8-K
Other material
confidence 74%
filed 2026-05-27
Item 8.01
Tonix Pharmaceuticals announced publication of a peer-reviewed Phase 1 clinical trial manuscript for TNX-1500 in the Journal of Clinical Immunology, demonstrating positive immunosuppressive efficacy in blocking T cell-dependent antibody responses at all tested doses. This clinical development milestone is material to investors assessing the company's pipeline progress and de-risking of the lead drug candidate.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-05-27
The filing discloses entry into Amendment No. 1 to an Exclusive License Agreement with MIRALOGX LLC on May 21, 2026 (Item 1.01). The amendment materially expands the Company's exclusive licensed territory for Ketamir-2 from the US, Canada, and Mexico to all countries with patent rights, and expands the licensed patent portfolio internationally across multiple jurisdictions. While the core economic terms remain unchanged, the territorial and patent scope expansion represents a material modification to the Company's rights and development strategy for a key asset, supporting continued global development and commercialization of Ketamir-2.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-05-27
The filing discloses termination of an exclusive worldwide license agreement with Wugen Inc. for ex vivo rights to HCW9201 and HCW9206 molecules, exercised pursuant to a suspension letter agreement dated May 30, 2025. This represents a material change in the Company's intellectual property licensing arrangements and strategic partnerships, affecting the Company's ability to develop and commercialize key assets.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-27
bioAffinity Technologies disclosed receipt of a patent allowance notification from the Mexican Institute of Industrial Property for a method related to lung cancer prediction using flow cytometry. While this is a positive intellectual property development, it does not fit cleanly into the standard 8-K event taxonomy (not earnings, M&A, executive changes, impairments, litigation, or cybersecurity). Patent allowances can be material to biotech/diagnostic companies' competitive positioning and valuation, warranting disclosure under Item 8.01 (Other Events).
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-27
This 8-K discloses the results of Shuttle Pharmaceuticals' 2026 Annual Meeting of Stockholders held on May 21, 2026, including voting outcomes on five proposals: election of four directors, ratification of Forvis Mazars as independent auditor, advisory vote on executive compensation, authorization for reverse stock splits (1-for-2 to 1-for-150), and meeting adjournment. All proposals were approved. This is a classic Item 5.07 shareholder vote results disclosure with detailed vote tallies and quorum information.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-05-27
SINTX received a notice from Nasdaq on May 22, 2026 (Item 3.01) stating the company is not in compliance with Listing Rule 5550(b)(1), which requires minimum stockholders' equity of $2.5 million. The company reported only $904,000 in stockholders' equity as of March 31, 2026 and does not meet alternative listing standards. The company has 45 days to submit a compliance plan or faces delisting risk, making this a material disclosure of continued listing failure under Item 3.01.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-05-27
The filing discloses entry into a material definitive agreement—an amended and restated facility agreement with L.I.A. Pure Capital Ltd. that increases the credit facility from EUR 6,000,000 to EUR 10,000,000 and modifies warrant terms with a new "price maintenance" anti-dilution provision. While this is primarily a financing arrangement rather than a traditional M&A transaction, Item 1.01 explicitly classifies it as a "Material Definitive Agreement," and the substantial increase in available credit and modification of dilutive warrant terms would materially affect investor assessment of the company's capital structure and financial obligations.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-05-27
Snail, Inc. received a deficiency letter from Nasdaq on March 26, 2026, for failing to meet the Net Income Requirement and alternative continued listing standards (market value of listed securities and stockholders' equity). The company submitted a Compliance Plan and received an Extension Letter on May 20, 2026, granting until September 22, 2026, to regain compliance, with explicit warning that failure to comply upon filing the Q3 2026 quarterly report will result in delisting of Class A Common Stock. This is a clear delisting risk disclosure under Item 8.01.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-05-27
The filing discloses issuance of a convertible promissory note for $3,052,787.68 (Item 1.01 and 3.02), which is convertible into common stock at $6.00 per share subject to stockholder approval. This is a dilutive equity issuance under Section 4(a)(2) and Regulation D. While the filing also contains a delisting notice (Item 3.01), the primary material event disclosed is the convertible note issuance, which represents a significant capital raise and potential equity dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-27
Item 5.07
This Item 5.07 disclosure reports the results of UMH Properties' annual shareholder meeting held on May 27, 2026, including voting outcomes for three proposals: election of four Class II directors, ratification of PKF O'Connor Davies as independent auditor, and an advisory vote on executive compensation. The detailed vote tallies (For/Against/Abstain/Broker Non-Votes) for each proposal are the core content, making this a textbook shareholder_vote_results event that is material to investors assessing governance and board composition.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-27
HWH International entered into a Securities Purchase Agreement on May 27, 2026 to sell 20 million shares of common stock and warrants to purchase 160 million additional shares to Smart Dynamics Technology Limited for $10 million. The filing explicitly discloses this as an unregistered sale under Item 3.02, relying on Section 4(a)(2) and Regulation D exemptions. The transaction grants the purchaser anti-dilution rights and board appointment rights, indicating significant dilution and control implications for existing shareholders.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 85%
filed 2026-05-27
The filing discloses results of Dermata's 2026 Annual Meeting of Stockholders held on May 27, 2026, with detailed voting outcomes on six matters including director elections, auditor ratification, and shareholder approval of equity issuances and warrant repricing. Item 5.07 explicitly reports the voting results with vote counts for each proposal, which is the primary disclosure focus of this 8-K. While Item 5.02 also mentions the Plan Amendment approval, the substantive content centers on the shareholder vote results required under Item 5.07.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-05-27
The filing discloses entry into a Master Services Agreement with ARK Capital Markets LLC on May 20, 2026, under Item 1.01 (Entry into a Material Definitive Agreement). The agreement involves substantial compensation arrangements including a 1.00% annual management fee on treasury assets, 2.2 million warrants exercisable at $1.01, potential milestone bonuses up to $10 billion capitalization, and 2.2 million restricted shares plus $250,000 annual cash compensation for a strategic advisor role. While this is primarily a services agreement rather than a traditional M&A transaction, the materiality, multi-year term (5+ years), and significant equity and cash consideration warrant classification as a material definitive agreement. The alternative classification of exec_compensation is less appropriate since the principal event is the entry into the agreement itself, not compensation to existing executives.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-05-27
The filing discloses Greenwave's receipt of a delinquency notification from Nasdaq on May 21, 2026, due to failure to timely file its Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Item 3.01 explicitly addresses "Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard," and the Company has until June 22, 2026 to submit a compliance plan or face potential delisting. This is a material event that directly threatens the Company's continued listing on Nasdaq Capital Market.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-05-27
Item 5.02
Shimon Steinmetz was appointed as Executive Vice President and Chief Financial Officer, effective on or prior to July 27, 2026, with a base salary of $500,000, bonus targets, RSAs, and PSUs, along with specified severance provisions.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-05-27
Item 5.02
The filing discloses both a director departure (Joseph F. Rossetti's resignation on May 21, 2026) and an appointment (Richard Xie appointed to the Board effective immediately to fill the vacancy). While both events occurred, the substantive focus and length of the disclosure centers on Mr. Xie's appointment, his qualifications, committee assignments (including as Chair of Audit and Compensation Committees), and independence determination. The appointment of a qualified director with significant finance and investment management experience to key committee leadership roles is the principal disclosed action and is material to investors.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-27
Item 3.02
Wheeler Real Estate Investment Trust issued 757,850 shares of common stock in exchange for preferred stock held by existing investors. This is a classic unregistered equity issuance under Section 3(a)(9) of the Securities Act, disclosed under Item 3.02. The transaction is dilutive to existing common shareholders and material to investor assessment of capital structure and ownership, even though no cash proceeds were received and preferred shares were retired.
View raw filing on EDGAR →
8-K
Earnings release
confidence 99%
filed 2026-05-27
Item 2.02
Item 2.02 discloses the issuance of a press release containing unaudited financial results for the fourth fiscal quarter and full fiscal year ended March 28, 2026. This is a standard earnings release disclosure, material to investors as it provides quarterly and annual financial performance data for Capri Holdings Ltd.
View raw filing on EDGAR →
8-K
Restatement
confidence 95%
filed 2026-05-27
Item 4.02
Management concluded that previously issued financial statements in the 10-K for fiscal year 2025 and 10-Q for Q1 2026 should no longer be relied upon due to revised accounting treatment of the Peeples Inc. acquisition from a business combination framework to an asset acquisition framework under ASC 805-50. The company is filing amended reports with restated financial statements.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-27
Item 5.07
Progyny held its Annual Meeting of Stockholders on May 27, 2026, with stockholders voting on five proposals: election of three Class I directors (Lloyd Dean, Kevin Gordon, Cheryl Scott), ratification of Ernst & Young LLP as auditor, advisory approval of named executive officer compensation, and two amendments to the Certificate of Incorporation eliminating supermajority voting requirements for director removal, bylaw amendments, and certain business combinations.
View raw filing on EDGAR →
8-K
Other material
confidence 74%
filed 2026-05-27
Item 8.01
NextNav announced an election to redeem all outstanding public warrants at $0.01 per warrant with a June 26, 2026 redemption date. This material capital structure event affects warrant holders' rights and the company's equity structure, disclosed via press release and other events notice.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-27
Item 5.07
This is a clear disclosure of shareholder voting results from NextNav Inc.'s 2026 Annual Meeting of Stockholders held on May 21, 2026. The filing reports final voting tallies for two proposals: (1) election of ten director nominees to the Board, with detailed vote counts for each nominee, and (2) ratification of Ernst & Young LLP as independent auditor. This is a textbook Item 5.07 disclosure of shareholder vote results, which is material to investors as it confirms board composition and auditor appointment.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-27
Item 8.01
Murphy USA disclosed the issuance of $500 million in 5.875% Senior Notes due 2034 under Item 8.01 (Other Events). While this is a material debt financing event that would affect investor assessment of the company's capital structure and financial obligations, it does not fit cleanly into the more specific event categories (e.g., it is not a restatement, covenant breach, or going-concern disclosure). The issuance of material debt is a significant corporate event, but the 8-K taxonomy lacks a dedicated "debt_issuance" category, making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
Exec departure
confidence 92%
filed 2026-05-27
Item 5.02
Debra Bigman informed the Board on May 18, 2026 of her decision not to stand for re-election to the Board of Directors upon expiration of her current term at the 2026 Annual Meeting. This constitutes a departure of a director from the Company's Board. The filing explicitly states her decision was not due to any disagreement with the Company, indicating a routine non-renewal rather than a contested departure, but it remains a material change in board composition.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-27
Item 5.07
This Item 5.07 disclosure presents the voting results from Civeo's 2026 Annual General Meeting of Shareholders, covering four proposals: election of six directors, advisory vote on named executive officer compensation, approval of an equity plan amendment increasing shares by 520,920, and ratification of Ernst & Young LLP as independent auditor. The detailed voting tallies (For/Against/Withheld/Broker Non-Votes) for each proposal are the core content, making this a textbook shareholder vote results disclosure material to investors assessing governance and capital allocation decisions.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-27
Item 5.07
This is a classic Item 5.07 disclosure of shareholder vote results from Backblaze's 2026 Annual Meeting held on May 26, 2026. The filing reports voting outcomes for two proposals: (1) election of Jocelyn Carter-Miller as a Class II director with 17.7M votes for and 8.8M against, and (2) ratification of Deloitte & Touche LLP as independent auditor with 40.1M votes for. Director elections and auditor ratifications are material governance matters affecting investor assessment of board composition and audit oversight.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-27
Item 8.01
Precision Biosciences disclosed late-breaking clinical data from its Phase 1 ELIMINATE-B trial presented at EASL Congress 2026, including new biopsy data demonstrating cccDNA elimination in PBGENE-HBV, establishment of pgRNA as a biomarker, and updated safety profile information. The data directly impacts investor assessment of the company's lead therapeutic candidate and pipeline viability.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-05-27
Item 8.01
The filing discloses completion of a $52.9 million acquisition of an indirect minority position in Manning & Napier, Inc., representing a material acquisition transaction. Although filed under Item 8.01 (Other Events), the substance is a completed M&A transaction that would materially affect investor assessment of the registrant's capital deployment and strategic positioning.
View raw filing on EDGAR →